CureVac N.V. Completes Acquisition by BioNTech, Initiates Nasdaq Delisting

summarizeSummary

CureVac N.V. has completed its post-offer reorganization, making BioNTech SE the sole owner of its operations, and has initiated the process to delist its shares from Nasdaq.

check_boxKey Events

• Acquisition Completed

  CureVac N.V. completed its post-offer reorganization, resulting in BioNTech SE becoming the sole owner of all CureVac's business operations.

• Public Shareholder Exit

  Following the reorganization, no public shareholders continue to hold CureVac Shares, as all shares were exchanged as part of BioNTech's offer.

• Nasdaq Delisting Initiated

  CureVac has requested Nasdaq to suspend trading and file Form 25 to delist its shares, with delisting expected to be effective on January 16, 2026.

• Deregistration from SEC

  CureVac Merger B.V., as successor, intends to file Form 15 to terminate SEC registration and suspend reporting obligations under the Exchange Act.

auto_awesomeAnalysis

This 6-K filing confirms the definitive end of CureVac N.V. as a publicly traded entity. The completion of BioNTech's exchange offer and subsequent post-offer reorganization means that all public shareholders have exited, and BioNTech now owns 100% of CureVac's business. The initiation of delisting from Nasdaq and the planned deregistration with the SEC will remove CureVac shares from public trading and terminate its reporting obligations. For investors, this marks the conclusion of their investment in CureVac's public shares, as the company transitions fully into a subsidiary of BioNTech.